Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable targets

Author:

Alors‐Pérez Emilia123,Blázquez‐Encinas Ricardo123,Moreno‐Montilla María Trinidad123,García‐Vioque Víctor123,Jiménez‐Vacas Juan Manuel123,Mafficini Andrea4,González‐Borja Iranzu5,Luchini Claudio4,Sánchez‐Hidalgo Juan M.167,Sánchez‐Frías Marina E.18,Pedraza‐Arevalo Sergio123,Romero‐Ruiz Antonio1,Lawlor Rita T.4,Viúdez Antonio59,Gahete Manuel D.1236ORCID,Scarpa Aldo4,Arjona‐Sánchez Álvaro17,Luque Raúl M.1236,Ibáñez‐Costa Alejandro123ORCID,Castaño Justo P.1236ORCID

Affiliation:

1. Maimonides Biomedical Research Institute of Córdoba (IMIBIC) Spain

2. Department of Cell Biology, Physiology, and Immunology University of Córdoba Spain

3. Reina Sofia University Hospital Córdoba Spain

4. ARC‐Net Research Centre and Section of Pathology of Department of Diagnostics and Public Health University and Hospital Trust of Verona Italy

5. OncobionaTras Lab, Navarrabiomed, Hospital Universitario de Navarra, Instituto de Investigación Sanitaria de Navarra‐IDISNA Universidad Pública de Navarra Pamplona Spain

6. CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn) Córdoba Spain

7. Surgery Service Reina Sofia University Hospital Córdoba Spain

8. Pathology Service Reina Sofia University Hospital Córdoba Spain

9. ICON plc Pamplona Spain

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, characterized by late diagnosis and poor treatment response. Surgery is the only curative approach, only available to early‐diagnosed patients. Current therapies have limited effects, cause severe toxicities, and minimally improve overall survival. Understanding of splicing machinery alterations in PDAC remains incomplete. Here, we comprehensively examined 59 splicing machinery components, uncovering dysregulation in pre‐mRNA processing factor 8 (PRPF8) and RNA‐binding motif protein X‐linked (RBMX). Their downregulated expression was linked to poor prognosis and malignancy features, including tumor stage, invasion and metastasis, and associated with poorer survival and the mutation of key PDAC genes. Experimental modulation of these splicing factors in pancreatic cancer cell lines reverted their expression to non‐tumor levels and resulted in decreased key tumor‐related features. These results provide evidence that the splicing machinery is altered in PDAC, wherein PRPF8 and RBMX emerge as candidate actionable therapeutic targets.

Funder

Fundación Eugenio Rodríguez Pascual

Junta de Andalucía

Ministerio de Ciencia e Innovación

Fondazione Cassa di Risparmio di Verona Vicenza Belluno e Ancona

Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición

European Cooperation in Science and Technology

Instituto de Salud Carlos III

Publisher

Wiley

Reference57 articles.

1. Pancreatic cancer: a review;Park W;JAMA,2021

2. Genomic analyses identify molecular subtypes of pancreatic cancer;Bailey P;Nature,2016

3. Altered RNA splicing by mutant p53 activates oncogenic RAS signaling in pancreatic cancer;Escobar‐Hoyos LF;Cancer Cell,2020

4. RNA splicing dysregulation and the hallmarks of cancer;Bradley RK;Nat Rev Cancer,2023

5. Regulation of pre‐mRNA splicing: roles in physiology and disease, and therapeutic prospects;Rogalska ME;Nat Rev Genet,2022

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3